Fredrik Schjesvold, Head of Oslo Myeloma Center at Oslo University Hospital, shared a post on LinkedIn:
“Today I want to talk about inconsistency in DMP/ Nye metoder.
In 2025, Blenrep was approved in Norway in 2nd line. The standard of care comparison was Isatuximab–Kd, appropriately so, since this was in fact our standard-of-care.
Now, cilta-cel was evaluated and declined. For the exact same patient population. However, this time DMP compared to DVd, which we haven’t used for years.
The comparison to Isa-Kd, which would be more correct, showed that cilta-cel was cheaper. But it was chosen to use the irrelevant DVd as comparator in the main analysis, even after the same system (Nye metoder) used Isa-Kd as comparator 6 months earlier, in the same population.
It’s very difficult to understand this decision. You would think that even DMP struggle to see the meaningfulness of comparing to something completely obsolete. ”
Other articles featuring Fredrik Schjesvold on OncoDaily.